Healthcare Value Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Healthcare Value Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-50,000	Closed	-$3.12M	–	37
2015 Q1	$3.12M	Buy	+50,000	New	+$2.91M	3.39%	12
2014 Q2	–	Sell	-75,000	Closed	-$3.96M	–	39
2014 Q1	$3.96M	Sell	75,000 -125,000	-63%	-$5.78M	2.59%	14
2013 Q4	$8.02M	Buy	200,000 +100,000	+100%	+$3.94M	5.88%	5
2013 Q3	$3.78M	Sell	100,000 -70,000	-41%	-$2.73M	3.3%	11
2013 Q2	$6.66M	Buy	+170,000	New	+$6.62M	4.83%	3

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Healthcare Value Capital's TEVA Position: Q3 2017 in Review

Healthcare Value Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 75,000 shares — an estimated $2.49M sold.

Healthcare Value Capital first reported a position in TEVA in Q3 2013 and held it in 10 quarters. The position peaked at $6.87M in Q1 2014. 536 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Healthcare Value Capital reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Healthcare Value Capital sold 75,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $2.49M.
Healthcare Value Capital first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Healthcare Value Capital's Teva Pharmaceuticals position peaked at $6.87M in Q1 2014.
536 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Healthcare Value Capital's 13F filing for Q3 2017, filed 13 Nov 2017.